Overview

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Treatments:
130-nm albumin-bound paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pemetrexed
Ramucirumab